Product Usage: For Research Use Only – Not for Human or Veterinary Use
This product is not a drug, food, cosmetic, or dietary supplement and has not been evaluated by the FDA. It is strictly intended for in vitro research by qualified professionals. Any use in humans or animals is strictly prohibited and may violate federal, state, or local laws, including the Federal Food, Drug, and Cosmetic Act. No therapeutic or diagnostic application is implied or permitted. The purchaser assumes all responsibility for compliance with applicable regulations.
Cagrilintide – 10mg
Cagrilintide is a lab-developed peptide designed as a long-acting version of amylin, a naturally occurring hormone. Researchers study this compound to better understand how it interacts with amylin-related pathways, as well as how it behaves alongside GLP-1 receptor signaling in controlled laboratory environments. This research focuses on how peptide compounds engage with complex signaling systems involved in metabolic processes. Cagrilintide is intended for research use only, and its effects outside of laboratory settings have not been established.
$200.00
Researchers who buy Cagrilintide research peptide are typically studying its behavior as a long-acting amylin-receptor agonist, structurally derived from human amylin (islet amyloid polypeptide) and engineered for extended plasma half-life via acylation and albumin-binding chemistry analogous to other long-acting peptide research compounds. The summary below reflects the published preclinical and clinical literature and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.
In this reference:
- What Is Cagrilintide?
- Proposed Mechanism of Action
- Chemical Identity
- Purity, Storage & Quality
- Research Applications
- What the Human Evidence Shows
- Frequently Asked Questions
What Is Cagrilintide?
Cagrilintide is a synthetic, long-acting amylin-receptor agonist, structurally based on human amylin (islet amyloid polypeptide), a hormone co-secreted with insulin by pancreatic beta cells. Researchers should be aware that cagrilintide is under active pharmaceutical clinical-development investigation, most prominently in fixed-dose combination with the GLP-1 receptor agonist semaglutide (studied under the developmental combination name CagriSema). As of this writing, neither cagrilintide as a standalone compound nor the CagriSema combination has completed FDA approval; this compound remains in clinical-trial-stage pharmaceutical development, distinct from the research-use-only material sold on this page.
Proposed Mechanism of Action
Published pharmacology describes cagrilintide as an agonist at amylin receptors, G-protein-coupled receptor complexes formed from the calcitonin receptor (CTR) combined with receptor-activity-modifying proteins (RAMPs). Recent published research identified amylin receptors 1 and 3, expressed in specific brainstem nuclei (the area postrema and nucleus tractus solitarius), as key mediators of cagrilintide’s studied effects on body-weight-related measures in tested animal models (PMID 40544431 and related 2026 mechanistic literature).
Published pharmacology distinguishes amylin-receptor signaling from GLP-1-receptor signaling as a separate, non-redundant satiety-related pathway — the basis for pharmaceutical-development interest in combining cagrilintide with GLP-1-receptor agonists such as semaglutide, on the hypothesis that engaging both pathways simultaneously produces effects exceeding either mechanism studied alone in tested models. Researchers sourcing cagrilintide as a standalone research compound are typically studying amylin-receptor pharmacology specifically, distinct from GLP-1-receptor mechanisms.
Chemical Identity
| Structural Basis | Long-acting human amylin (IAPP) analog |
| Receptor Target | Amylin receptors (CTR + RAMP complexes) |
| Appearance | White to off-white lyophilized powder |
Purity, Storage & Quality
First Class Science supplies this Cagrilintide research peptide vial at research-grade purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at our Certificate of Analysis page, listing the specific lot’s purity result and test date.
Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions, both of which are associated with accelerated peptide degradation in handling literature.
Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.
Preparing Solutions for Laboratory Use
Laboratories reconstituting lyophilized cagrilintide for in vitro or animal-model research typically follow standard peptide-handling practice: the vial is brought to room temperature before opening, and a diluent — commonly reconstitution solution or sterile water for injection (SWFI) — is added slowly down the interior wall of the vial rather than directly onto the lyophilized material, to reduce foaming and mechanical stress on the peptide. The vial is then gently swirled, never shaken, until the powder is fully dissolved.
Stock-solution concentration for a given protocol is calculated by dividing the total peptide mass in the vial by the volume of diluent added, and that calculation should be recorded in the study’s protocol documentation. This page describes general laboratory reconstitution practice for research use and is not a dosing guide for human or animal administration.
Quality Control Methodology
Each production batch of this Cagrilintide research peptide undergoes independent third-party testing before release. High-performance liquid chromatography (HPLC) confirms purity by measuring the proportion of the target peptide relative to synthesis by-products or degradation fragments. Mass spectrometry separately confirms molecular identity. Both results are recorded on the batch’s published Certificate of Analysis, letting researchers independently verify identity and purity rather than relying on manufacturer claims alone.
Who Should Buy Cagrilintide Research Peptide
Researchers who buy Cagrilintide from First Class Science are typically university and academic laboratories, contract research organizations (CROs), and biotechnology R&D teams running in vitro amylin-receptor-binding assays or animal-model studies on amylin-receptor pharmacology. First Class Science requires that all research-peptide orders be placed by parties who acknowledge and agree to the research-use-only terms stated on this page prior to purchase.
Research Applications
The published literature on cagrilintide spans several distinct research areas, all part of an active and evolving clinical-development pharmacology program. Each is summarized below strictly as a description of what has been studied in animal or controlled clinical-trial models — not as a claim about effects for any individual using this product.
Amylin-Receptor Pharmacology Research
Recently published mechanistic research has identified specific brainstem amylin-receptor subtypes (AMY1R, AMY3R) as mediators of cagrilintide’s studied body-weight-related effects in animal models, advancing understanding of amylin-receptor signaling as a distinct pathway from GLP-1-receptor mechanisms.
Dual-Pathway Combination Research
Because amylin and GLP-1 receptor pathways are studied as non-redundant, published clinical-development research has examined co-administration of cagrilintide with semaglutide, with published phase 3 trial data reporting on combined-pathway outcomes in controlled clinical-trial populations (detailed in Human Evidence below).
What the Human Evidence Shows
Researchers evaluating cagrilintide should know that it is currently the subject of substantial, active human clinical-trial research as a candidate pharmaceutical, but has not completed FDA approval as of this writing. A published phase 3, 68-week, multicenter, randomized, double-blind, placebo- and active-controlled trial (REDEFINE 1) examined coadministered cagrilintide and semaglutide in adults with overweight or obesity without diabetes, reporting body-weight-reduction measures relative to placebo and to either compound studied alone (N Engl J Med. 2025; PMID 40544431). A companion trial examined the same combination in adults with overweight or obesity and type 2 diabetes (PMID 40544432).
This is active, ongoing clinical-trial-stage pharmaceutical-development research, not an approved product — cagrilintide and the CagriSema combination have not completed FDA approval, are not evaluated by the FDA for safety or efficacy outside the clinical-trial setting in which these results were generated, and this research-use-only sale does not support human self-administration for any purpose, weight-management or otherwise. Researchers should characterize findings from this page accordingly in any grant application or protocol design — as findings from a specific, controlled, active clinical-trial program, not an established or approved therapeutic profile.
Common Research Study Designs
Published studies referenced throughout this page typically fall into two designs: preclinical/mechanistic research identifying specific amylin-receptor subtypes and their tissue distribution; and large, controlled phase 3 randomized clinical trials, currently active as part of an ongoing pharmaceutical-development program. Understanding which design underlies a given finding — and that this remains investigational, unapproved research — is important context for interpreting the strength of any individual claim in the literature.
Frequently Asked Questions
What is the purity of this Cagrilintide research peptide?
Every batch is independently verified via third-party HPLC and mass-spectrometry testing, with a Certificate of Analysis published for each lot.
How should Cagrilintide research peptide be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.
Is Cagrilintide approved for human or animal use?
No. Cagrilintide, whether alone or in the CagriSema combination with semaglutide, has not completed FDA approval as of this writing and remains in active clinical-trial-stage pharmaceutical development. It is sold here exclusively for in vitro and laboratory research use, and this sale does not constitute or support any human or animal use.
Has Cagrilintide been tested in humans?
Yes, extensively, as part of an active, ongoing pharmaceutical clinical-development program. Published phase 3 trials (PMID 40544431, PMID 40544432) examined cagrilintide co-administered with semaglutide in controlled clinical-trial populations. This is investigational research, not an approved therapeutic record.
What is the proposed mechanism of Cagrilintide in research models?
Cagrilintide is studied as an agonist at amylin receptors (CTR/RAMP complexes), a pathway distinct from and studied as complementary to GLP-1-receptor signaling.
What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date, allowing researchers to independently verify the identity and purity of the specific batch they receive.
Can Cagrilintide research peptide be shipped internationally?
Shipping availability and any import restrictions for research peptides vary by destination country and are subject to change; researchers should confirm their local import regulations for research-use-only compounds before ordering.
Shipping, Handling & Compliance
This Cagrilintide research peptide ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.
Order tracking, batch-specific documentation requests, and general product questions can be directed to First Class Science customer support, which can confirm current lead times and any destination-specific documentation a receiving institution may require for its own compliance records.
Disclaimer: The research summarized above is drawn from third-party published studies, including active clinical-trial-stage pharmaceutical research. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.
⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.